Neonatal Sepsis at Neonatal Intensive Care Units in Ghana
Launched by STEPHANIE BJERRUM · Nov 23, 2018
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
Background In 2012, it was estimated that approximately 680,000 neonatal deaths in developing countries were due to bacterial infections, with an incidence risk of 7.6% and a case fatality risk of 9.8. A major proportion of neonatal infections are expected to be health-care associated, due to inadequate infrastructure and resources for infection control and prevention. Hospital acquired infections(HAIs) are associated with multi-drug resistant (MDR) bacteria, which increases the risk of therapeutic failure due to the limited choice of available antibiotics. HAIs also lead to extended durati...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Admission NICU
- • Birth weight ≥750 Grams
- • ≤48 hours of age at time of enrolment
- • Consent to participate obtained from legal guardian
- Exclusion Criteria:
- • Neonates with severe congenital malformations
- • Neonates who have undergone surgical procedure
About Stephanie Bjerrum
Stephanie Bjerrum is a dedicated clinical trial sponsor with extensive experience in the development and management of innovative therapeutic interventions. Committed to advancing medical research, she oversees the design, implementation, and monitoring of clinical trials, ensuring adherence to regulatory standards and ethical guidelines. With a strong focus on patient safety and data integrity, Stephanie collaborates closely with multidisciplinary teams to facilitate the successful execution of trials that contribute to the development of new treatments and improve health outcomes. Her leadership in the field is marked by a passion for fostering collaboration and driving scientific progress.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Accra, , Ghana
Patients applied
Trial Officials
Appiah Korang Labi, MD
Principal Investigator
Department of Int. Health and Immunlogy Microbiology, University og Copenhagen
Jørgen Kurtzhals, Professor
Study Director
Department of Int. Health and Immunlogy Microbiology, University og Copenhagen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials